NEW YORK - IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies with a current market capitalization of $23.42 million, has announced encouraging Phase ...

Study Progresses to Fourth Higher 90 mg/m2Dose CohortCompelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast ...

Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have invented an oral formulation of ...

Pedal the Cause announces funding for eight new cancer research projects and a clinical trial at Siteman Cancer Center.

Acquired miR-142 deficit in leukemic stem cells has been associated with chronic myeloid leukemia blast crisis. Here the authors show that acquired miR-142 deficit in T cells further enables ...

All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...

Among patients with acute myeloid leukemia (AML) in remission following second-line ... has recommended the continuation of the clinical trial without any modifications. Notably, the IDMC went on to ...

Blinatumomab, which recently completed clinical trials and has won approval from the FDA, is a drug designed to treat acute lymphoblastic leukemia, one of the most common types of blood and bone ...

new treatment options are emerging through ongoing research. In B-PLL, immature forms of B-lymphocytes, called prolymphocytes, divide and multiply rapidly in the bone marrow and blood. Leukemia is ...

These cells fight leukemia by boosting the immune response ... much more work has to be done before the team can head to clinical trials with the hope to improve outcomes for patients with ...